Market capitalization | $16.80b |
Enterprise Value | $11.29b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.23 |
P/S ratio (TTM) P/S ratio | 3.31 |
P/B ratio (TTM) P/B ratio | 1.41 |
Revenue growth (TTM) Revenue growth | -44.06% |
Revenue (TTM) Revenue | $5.07b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
28 Analysts have issued a Moderna forecast:
28 Analysts have issued a Moderna forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5,073 5,073 |
44%
44%
|
|
Gross Profit | 3,088 3,088 |
7%
7%
|
|
EBITDA | -2,370 -2,370 |
7%
7%
|
EBIT (Operating Income) EBIT | -2,701 -2,701 |
1%
1%
|
Net Profit | -2,224 -2,224 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Stéphane Bancel |
Employees | 5,600 |
Founded | 2010 |
Website | www.modernatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.